Immuno-Eclipse radiotherapy controlled bulky tumor models through antitumor immunity
Immuno-Eclipse radiotherapy improved bulky tumor control in mice through natural killer and cytotoxic T-cell immunity.
Immuno-Eclipse radiotherapy improved bulky tumor control in mice through natural killer and cytotoxic T-cell immunity.
A single-arm phase 1/2 trial reported a 39.1% pathologic complete response rate among resected patients, with grade 4 toxicities in 10%.
Adjunctive hydrogen gas inhalation was associated with numerically fewer moderate toxicities and exploratory serum metabolomic changes during head and neck chemoradiotherapy.
In 24 surgically confirmed cases, three radiomic features differed nominally between pure osteoradionecrosis and osteoradionecrosis with recurrence.
Combined high lactate dehydrogenase-5 expression and low tumor-infiltrating lymphocyte density independently identified higher biochemical relapse risk after prostate radiotherapy.
Three of four patients completed final imaging and lung stereotactic ablative radiotherapy within one assisted breath-hold, with only grade 1 adverse events.
Five-fraction helical tomotherapy achieved favorable organ sparing, while the planning target volume-to-breast ratio was associated with higher ipsilateral breast dose.
Adding early stereotactic body radiotherapy to neoadjuvant chemoimmunotherapy was associated with median progression-free survival of 12.5 versus 6.6 months.
Regional lymph node irradiation was linked to attenuated local cytokine shifts and nodal damage and cell-death signatures after sinonasal stereotactic radiotherapy.
Oxygen-ion irradiation showed higher biological effectiveness and more persistent DNA damage than carbon ions or photons in pancreatic cancer cells.
Splitting eight fractions between inhale and exhale breath-holds reduced maximum rib dose from 67.9 to 33.5 Gy without compromising target coverage.
Regional diffusion changes distinguished patients who developed contrast-enhancing brain lesions as early as six months after proton therapy.
Computed tomography-derived muscle measures ranked highly for toxicity and quality of life, but added little predictive value beyond established clinical factors.
Radiotherapy increased tumor uptake of PDL1-targeted radionuclide therapy, while antibody co-dosing reduced splenic trapping and restored antitumor efficacy in mice.
Convergent 60 keV photons matched orthovoltage radiation and showed comparable or greater biological effectiveness than 6 MV photons, depending on cell type.